| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Activation of natural killer T cells enhances the function of regulatory T-cell therapy in suppressing murine GVHD
|
Hirai, Toshihito
|
|
|
5 |
11 |
p. 2528-2538
|
artikel
|
| 2 |
Axicabtagene ciloleucel in vivo expansion and treatment outcome in aggressive B-cell lymphoma in a real-world setting
|
Ayuk, Francis A.
|
|
|
5 |
11 |
p. 2523-2527
|
artikel
|
| 3 |
BCL-XL antagonism selectively reduces neutrophil life span within inflamed tissues without causing neutropenia
|
Carrington, Emma M.
|
|
|
5 |
11 |
p. 2550-2562
|
artikel
|
| 4 |
Blueprint for the discovery of biomarkers of toxicity and efficacy for CAR T cells and T-cell engagers
|
Paczesny, Sophie
|
|
|
5 |
11 |
p. 2519-2522
|
artikel
|
| 5 |
Editorial Board
|
|
|
|
5 |
11 |
p. i
|
artikel
|
| 6 |
Effect of DNMT3A variant allele frequency and double mutation on clinicopathologic features of patients with de novo AML
|
Narayanan, Damodaran
|
|
|
5 |
11 |
p. 2539-2549
|
artikel
|
| 7 |
Gupta V, Kennedy JA, Capo-Chichi J-M, et al. Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL–negative MPN in blast phase. Blood Adv. 2020;4(21):5562-5573.
|
|
|
|
5 |
11 |
p. 2518
|
artikel
|
| 8 |
Gupta V, Kim S, Hu Z-H, et al. Comparison of outcomes of HCT in blast phase of BCR-ABL1 − MPN with de novo AML and with AML following MDS. Blood Adv. 2020;4(19):4748–4757.
|
|
|
|
5 |
11 |
p. 2515
|
artikel
|
| 9 |
Liquid biopsy in extranodal NK/T-cell lymphoma: a prospective analysis of cell-free DNA genotyping and monitoring
|
Qi, Fei
|
|
|
5 |
11 |
p. 2505-2514
|
artikel
|
| 10 |
Tissue factor pathway inhibitor and bleeding tendency: can hormonal state explain the differences?
|
Dahm, Anders Erik Astrup
|
|
|
5 |
11 |
p. 2516-2517
|
artikel
|
Tijdschrift beschrijving